Home / Business News (page 2)

Business News

Pfizer Exercises Option to License AnTolRx’s Immune Tolerance Therapy for Treatment of Type 1 Diabetes

CAMBRIDGE, Mass., March 5, 2019 /PRNewswire/ — AnTolRx, Inc., a private biotechnology company and a leader in immune tolerance, today announced that Pfizer Inc. (NYSE: PFE) has exercised the option granted under a June 2016 agreement to license an immune tolerance therapy from AnTolRx’s Type 1 diabetes research program. The …

Read More »

Biogen to Acquire Nightstar Therapeutics Gaining Pipeline of Gene Therapy Candidates in Ophthalmology

CAMBRIDGE, Mass., March 04, 2019 (GLOBE NEWSWIRE) — Biogen (Nasdaq: BIIB) today announced that it has entered into an agreement to acquire Nightstar Therapeutics (NST; Nasdaq: NITE), a clinical-stage gene therapy company based in London, United Kingdom, which is focused on adeno-associated virus (AAV) treatments for inherited retinal disorders. Under …

Read More »

NantKwest Signs Worldwide License Agreement with ProMab to Develop Select Next Generation Targeted Natural Killer Cell Therapies

SAN DIEGO–(BUSINESS WIRE)–NantKwest, Inc. (Nasdaq:NK), a leading clinical-stage Natural Killer (NK) cell based therapeutics company, and ProMab Biotechnologies today announced the establishment of a worldwide license to a B-Cell Maturation Antigen (BCMA) targeted antibody sequence for multiple myeloma along with an option for up to five undisclosed targeting sequences for exclusive …

Read More »

Clinigen and Eiger Launch Worldwide Managed Access Program for Lonafarnib for Patients with Progeria and Progeroid Laminopathies

BURTON UPON TRENT, England–(BUSINESS WIRE)–Clinigen Group plc (AIM:CLIN, ‘Clinigen’), the global pharmaceutical and services company, has partnered with Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR, ‘Eiger’) to launch a worldwide lonafarnib Managed Access Program for patients with Progeria and Progeroid Laminopathies. Progeria, also known as Hutchinson-Gilford Progeria Syndrome, is a rare and fatal …

Read More »

MaxCyte and Kite Enter Multi-Drug CAR-T Technology Deal

Gaithersburg, Maryland – 01 March 2019: MaxCyte (LSE: MXCT, MXCS), the global cell-based medicines and life sciences company, announced today that it has expanded its relationship with Kite, a Gilead Company, by entering into a multi-drug clinical and commercial agreement. Under the terms of the agreement, Kite will use MaxCyte’s Flow Electroporation® Technology to enable …

Read More »

Sarepta Exercises Option to Acquire Myonexus Therapeutics and its Gene Therapy Candidates

CAMBRIDGE, Mass., Feb. 27, 2019 (GLOBE NEWSWIRE) — Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, announced today that it has exercised its option to acquire Myonexus Therapeutics, a clinical-stage biotechnology company developing transformative gene therapies for five LGMDs: LGMD2E, LGMD2D, LGMD2B, LGMD2C and LGMD2L. Subject to satisfaction of …

Read More »

Apellis and SFJ Pharmaceuticals Collaborate for APL-2 in Hematologic Indications

WALTHAM Mass., and CRESTWOOD, Ky., Feb. 28, 2019 (GLOBE NEWSWIRE) —  Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, today announced a novel, risk-sharing collaboration to support the development of APL-2 in hematologic …

Read More »

AbCellera and Denali Therapeutics Expand Deal to Discover Therapeutic Antibodies for Neurological Diseases

VANCOUVER, British Columbia–(BUSINESS WIRE)–AbCellera today announced an expanded collaboration with Denali Therapeutics Inc. (NASDAQ:DNLI) to discover antibodies as therapies for neurological indications. AbCellera will generate panels of antibodies for up to eight drug targets nominated by Denali using AbCellera’s high-throughput, ultra-deep single-cell immune profiling capabilities. This multi-target deal expands the scope of the …

Read More »

Danaher to Acquire GE’s Biopharma Business for $21.4 Billion

WASHINGTON, Feb. 25, 2019 /PRNewswire/ — Danaher Corporation (NYSE: DHR) (“Danaher” or the “Company”) announced today that it has entered into a definitive agreement with General Electric Company (“GE”) (NYSE: GE) to acquire the Biopharma business of GE Life Sciences (“GE Biopharma”) for a cash purchase price of approximately $21.4 billion. Given anticipated …

Read More »

Roche to Acquire Gene Therapy Firm Spark Therapeutics for $4.3 Billion

Roche (SIX: RO, ROG; OTCQX: RHHBY) and Spark Therapeutics, Inc. (NASDAQ: ONCE) today announced that they have entered into a definitive merger agreement for Roche to fully acquire Spark Therapeutics at a price of US$ 114.50 per share in an all-cash transaction. This corresponds to a total transaction value of …

Read More »